R&D News | pharmaphorum

News

Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.

News

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

News

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

News

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

News

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.

News

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.